💊Dainippon Sumitomo announces the launch of “Seebri ™ Neohaler®” for the treatment of chronic obstructive pulmonary disease (COPD) in the United States  20171020

JPN, Pharmaceutical

💊Establish mass production technology of Toyobo and HMT, enzymes for depression related biomarkers Toyobo and Human Metabolome Technologies have established mass-production technologies for enzymes used for measuring depression-related biomarkers through collaborative research.

JPN, Pharmaceutical

💊Completion of Acquisition of NeuroDerm (100% Ownership)  20171018

JPN, Pharmaceutical

Posts navigation